Why is Pharmaids Pharmaceuticals Ltd falling/rising?

Recent Price Movements and Volatility

The stock has been under pressure for the past two days, losing 7.37% in that period. Despite touching an intraday high of ₹46.99, the shares ultimately fell to their intraday low of ₹42.13, which is just 0.31% above the 52-week low. The wide trading range of ₹4.86 and an intraday volatility of 5.45% indicate heightened uncertainty among investors. Notably, the weighted average price suggests that more volume was traded near the lower end of the price range, signalling selling pressure.

Pharmaids Pharmaceuticals is currently trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This technical weakness often discourages short-term and medium-term investors, contributing to further declines.

Stock Performance Versus Market Benchmarks

Over the past week, the stock has fallen by 10.93%, significantly underperforming the Sensex, which declined by only 2.43%. The one-month and year-to-date returns also show a similar pattern, with Pharmaids dropping 12.94% and 11.60% respectively, while the Sensex fell by 4.66% and 4.32% in the same periods. The most striking underperformance is over the last year, where Pharmaids Pharmaceuticals lost 43.45%, in stark contrast to the Sensex’s gain of 6.56%. This divergence highlights the stock’s struggles amid broader market gains.

Fundamental Weaknesses Weighing on the Stock

Pharmaids Pharmaceuticals’ long-term fundamentals remain weak, which is a key factor behind the stock’s decline. The company has reported operating losses and a negative EBITDA, indicating that it is not generating sufficient earnings before interest, taxes, depreciation, and amortisation. Over the past five years, operating profit has declined at an annual rate of 1.81%, signalling deteriorating profitability.

The company’s ability to service its debt is also poor, with an average EBIT to interest ratio of -8.31. This negative ratio suggests that earnings before interest and taxes are insufficient to cover interest expenses, raising concerns about financial stability. Additionally, interest expenses for the nine months ending September 2025 have surged by 207.48% to ₹3.29 crores, further straining the company’s finances.

Profitability has also taken a hit, with profits falling by 34% over the past year. This decline in earnings, coupled with the stock’s 43.45% negative return in the same period, underscores the challenges faced by Pharmaids Pharmaceuticals in maintaining investor confidence.

Market Sentiment and Shareholder Composition

Investor sentiment appears cautious, as reflected in the rising delivery volume of 2.43 thousand shares on 22 January, which is 20.91% higher than the five-day average. Despite this increased participation, the stock continues to underperform its sector by 3.71% on the day, indicating that selling pressure outweighs buying interest.

The majority of shareholders are non-institutional, which can sometimes lead to higher volatility and less stable shareholding patterns. This shareholder composition may contribute to the stock’s heightened price swings and vulnerability to market sentiment shifts.

Conclusion: Why Pharmaids Pharmaceuticals Is Falling

The decline in Pharmaids Pharmaceuticals Ltd’s share price on 23 January is primarily driven by its weak financial fundamentals, including operating losses, negative EBITDA, and a deteriorating ability to service debt. The company’s poor profitability and rising interest expenses have eroded investor confidence, reflected in the stock’s significant underperformance relative to the Sensex and its sector peers over multiple time frames.

Technical indicators also paint a bearish picture, with the stock trading below all major moving averages and exhibiting high volatility and selling pressure near its 52-week low. Although there is increased investor participation, it has not been sufficient to reverse the downward trend.

Given these factors, Pharmaids Pharmaceuticals remains a risky investment, and its shares are likely to continue facing downward pressure unless there is a marked improvement in operational performance and financial health.

Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →